相关实验视频

Updated: Jul 15, 2025

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

从诊断到临床试验的间性肌肉肉瘤

Monika Dudzisz-Śledź¹, Monika Kondracka^1,2, Monika Rudzińska^1,2

¹Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.

|September 28, 2023

概括

介质细胞胆固醇瘤 (MCS) 是一种罕见的癌症. 本综述探讨了诊断生物标志物,并讨论了针对性疗法,如蛋白激酶抑制剂,用于先进的MCS治疗.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
癌症研究癌症研究

背景情况:

介质性胆固醇瘤 (MCS) 是一种罕见的骨瘤,预后不佳.
目前局部MCS的治疗是手术切除;晚期/转移病例缺乏确定的指导方针.
由于其发病率较低,MCS的潜在病理在很大程度上仍未知.

研究的目的:

审查有关中性软骨肉瘤 (MCS) 诊断和治疗的当前知识.
突出MCS诊断的免疫学和分子生物标志物.
讨论MCS的预后因素和新兴的治疗策略.

主要方法:

关于介质性肌肉肉瘤 (MCS) 的现有研究的文献综述.
对涉及MCS病变的分子途径的分析,包括PDGF/PI3K/AKT,PKC/RAF/MEK/ERK,pRB和BCL2.
检查诊断生物标志物和预后因素.

主要成果:

确定了特定分子通路 (例如,PDGF/PI3K/AKT) 和BCL2过度表达在MCS病变发生过程中的潜在作用.
突出免疫和分子生物标志物有助于MCS诊断.
讨论了与患者结果相关的预后和预测因素.

结论:

蛋白激酶和BCL2抑制剂代表了MCS的潜在向疗法.
新兴的治疗方法包括向疗法和临床试验,研究蛋白激酶抑制剂和DR5激动剂.
对MCS病原和新治疗方法的进一步研究对于改善患者的治疗结果至关重要.

关键词:

介质细胞混凝土肉瘤 (chondrosarcoma)预后预后预后罕见的肉瘤是一种罕见的肉瘤.治疗治疗治疗治疗治疗治疗

更多相关视频

The In ovo CAM-assay as a Xenograft Model for Sarcoma

The In ovo CAM-assay as a Xenograft Model for Sarcoma

Published on: July 17, 2013

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Published on: October 14, 2016

相关概念视频

Clinical Trials: Overview

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...